ArticleEClinicalMedicine2026

E7386 plus lenvatinib in patients with advanced endometrial cancer that progressed on platinum-based chemotherapy and an anti-PD-(L)1 immunotherapy: a single-arm, open-label, global phase 1b/2 dose-expansion cohort.

Jung-Yun Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.